The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The move is expected to be crucial during health crises
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
Subscribe To Our Newsletter & Stay Updated